IP Library Granted Patent US 10,610,551
Granted Patent B2
US 10,610,551 · App. 16/364,144 · Granted Apr 7, 2020

Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

Inventor: Thomas J. Borody (Five Dock, AU)
Assignee: Crestovo Holdings, Inc.
A61K35/74A61K9/4891A61K35/24A61K35/742A61M5/142A61P1/12C12N1/00A61B10/0038A61K9/4875A61K2035/115A61M31/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,610,551
App. No.
16/364,144
Granted
Apr 7, 2020
Kind
B2
Abstract

In alternative embodiments, the invention provides compositions, e.g., formulations, used for gastric, gastrointestinal and/or colonic treatments or lavage, e.g., orthostatic lavage, e.g., for inducing the purgation (e.g., cleansing) of a gastrointestinal (GI) tract, including a colon; and methods for making and using them. In alternative embodiments, compositions and methods of the invention are used for the stabilization, amelioration, treatment and/or prevention of constipation, for the treatment of abdominal pain, particularly non-specific abdominal pain, and diarrhea, including diarrhea caused by a drug side effect, a psychological condition, a disease or a condition such as Crohn's Disease, a poison, a toxin or an infection, e.g., a toxin-mediated traveler's diarrhea, or C. difficile or the pseudo-membranous colitis associated with this infection. In alternative embodiments, the invention provides pharmaceuticals and products (articles) of manufacture for delivering these compositions and formulations to an individual, e.g., a human or an animal. The invention also provides devices for delivering a fecal material to a patient.

Claims (24)

1. A container comprising: a pharmaceutical composition comprising a lyophilized bacterial composition, wherein the bacterial composition comprises one or more cultured anaerobic bacterial strains derived from a stool of a healthy human donor, wherein the one or more bacterial strains is of the genus Bacteroides or the phylum Firmicutes; and

an oxygen scavenging material,

wherein the pharmaceutical composition comprises a cryoprotectant.

2. The container of claim 1 , wherein the oxygen scavenging material comprises a pellet.

3. The container of claim 1 , wherein the oxygen scavenging material comprises a polymer or polymer blend.

4. The container of claim 1 , wherein the container simulates a partially anaerobic environment.

5. The container of claim 1 , wherein the oxygen scavenging material comprises an antioxidant.

6. The container of claim 5 , wherein the antioxidant comprises cysteine.

7. The container of claim 1 , wherein the one or more bacterial strains comprises a plurality of bacterial strains.

8. The container of claim 7 , wherein each of the plurality of bacterial strains is cultured as a pure culture.

9. The container of claim 7 , wherein the plurality of bacterial strains are cultured as a mixed culture.

10. The container of claim 1 , wherein the one or more bacterial strains is of the phylum Firmicutes.

11. The container of claim 1 , wherein the one or more bacterial strains is of the genus Bacteroides and the phylum Firmicutes.

12. A capsule comprising a pharmaceutical composition comprising:

(i) a powdered bacterial mixture comprising lyophilized bacteria from at least two cultured anaerobic bacterial strains, wherein the at least two cultured anaerobic bacterial strains are derived from a stool of one or more healthy human donors, and wherein the at least two cultured anaerobic bacterial strains are of the genus Bacteroides or the phylum Firmicutes;

(ii) a cryoprotectant; and

(iii) an oxygen scavenger.

13. The capsule of claim 12 , wherein the oxygen scavenger comprises an antioxidant.

14. The capsule of claim 13 , wherein the antioxidant comprises cysteine.

15. The capsule of claim 12 , wherein the cryoprotectant comprises trehalose.

16. The capsule of claim 12 , wherein each of the at least two anaerobic bacterial strains is cultured as a pure culture.

17. The capsule of claim 12 , wherein the at least two anaerobic bacterial strains are cultured as a mixed culture.

18. The capsule of claim 12 , wherein at least one of the at least two anaerobic bacterial strains is of the phylum Firmicutes.

19. The capsule of claim 12 , wherein the at least two anaerobic bacterial strains are of the genus Bacteroides and the phylum Firmicutes.

Assignments (3)
CHANGE OF NAME Recorded Dec 31, 2020
From: CRESTOVO HOLDINGS LLC
To: FINCH THERAPEUTICS HOLDINGS LLC
Reel/Frame 054883/0280 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: CRESTOVO LLC
To: CRESTOVO HOLDINGS LLC
Reel/Frame 048729/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2019
From: BORODY, THOMAS J.
To: CRESTOVO LLC
Reel/Frame 048729/0651 →
Priority Claims (1)
AU 2010903474 · Aug 4, 2010 · national
Continuity (11)
Continuation 16118400 · Aug 30, 2018
Continuation 15975456 · May 9, 2018
Continuation 15950939 · Apr 11, 2018
Continuation 15782519 · Oct 12, 2017
Continuation 15093679 · Apr 7, 2016
Continuation 13813915
Provisional Application 61494363 · Jun 7, 2011
Provisional Application 61483487 · May 6, 2011
Provisional Application 61451087 · Mar 9, 2011
Provisional Application 61450099 · Mar 7, 2011
Related Publication 20190216860A1 · Jul 18, 2019
Cited By (1)
US 12,409,085